Dihexa and PE-22-28: the cognitive peptides on the frontier

The Cognitive Holy Grail

If there is one category of compounds that generates the most intense interest -- and the most reckless self-experimentation -- it is cognitive enhancers. The promise of sharper thinking, better memory, and enhanced focus has driven people to try everything from racetams to microdosing to research peptides with barely any published data.

Dihexa and PE-22-28 sit at the extreme end of this spectrum. Both target fundamental neuroplasticity mechanisms. Both have generated excitement based on genuinely intriguing preclinical findings. And both have evidence bases so thin that using them in a human body is essentially running an uncontrolled Phase I trial on yourself.

This article is for people who want to understand what these compounds actually are, what the science actually shows, and why the gap between petri dish results and safe cognitive enhancement is wider than most forums suggest.

Dihexa: The HGF/MET Activator

Background and Origin

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed by Joseph Harding's laboratory at Washington State University. Harding's group had spent years studying the angiotensin IV (AngIV) / AT4 receptor system and its role in memory and cognition.

The AT4 receptor was later identified as hepatocyte growth factor (HGF) receptor, also known as c-Met or MET. This was a breakthrough: it connected the angiotensin system to a growth factor pathway known to promote cell survival, tissue repair, and -- critically -- synaptogenesis (the formation of new synaptic connections between neurons).

Dihexa was designed as a stable, metabolically resistant analog that could activate the HGF/MET system more potently than the natural ligands.

The Key Study

The foundational paper was published in 2013 in the Journal of Pharmacology and Experimental Therapeutics by McCoy et al. from Harding's lab. The headline findings:

• Dihexa promoted new synapse formation in organotypic hippocampal slice cultures
• In scopolamine-impaired rats, Dihexa restored cognitive performance in the Morris water maze at doses as low as 2 pmol/kg
• The authors described Dihexa as being "seven orders of magnitude more potent than BDNF" at inducing spinogenesis (new dendritic spine formation)

That "seven orders of magnitude" claim spread through the nootropics community like wildfire. And it is technically what the paper states. But context matters enormously here.

Why the "10 Million Times More Potent" Claim Is Misleading

The potency comparison between Dihexa and BDNF is not a clean apples-to-apples comparison:

• Different mechanisms entirely. BDNF works through TrkB receptors. Dihexa works through HGF/MET. Comparing their potency at spinogenesis is like comparing aspirin to morphine at pain relief -- they work through completely different systems, so the comparison tells you about the assay conditions, not about relative therapeutic value.
• In-vitro potency does not equal in-vivo efficacy. A compound can be extraordinarily potent in a cell culture system and completely useless in a living organism due to metabolism, distribution, protein binding, and blood-brain barrier penetration.
• The metric was spinogenesis in hippocampal slices. This is a specific laboratory readout, not a measure of cognitive enhancement. More spines does not automatically mean better cognition.

The HGF/MET Problem

Here is where Dihexa gets genuinely concerning. The HGF/MET pathway is one of the most well-characterized oncogenic signaling systems in cancer biology:

• MET amplification drives multiple cancer types including non-small cell lung cancer, gastric cancer, and hepatocellular carcinoma
• HGF/MET signaling promotes tumor cell proliferation, invasion, metastasis, and angiogenesis
• Multiple pharmaceutical companies have spent billions developing MET inhibitors (cabozantinib, capmatinib, tepotinib) specifically to shut down this pathway in cancer patients

Dihexa does the opposite. It activates the same system that oncologists are trying to suppress.

Does this mean Dihexa causes cancer? Not necessarily. Context matters -- HGF/MET signaling plays different roles in healthy tissue versus tumor microenvironments. Brief activation in normal brain tissue might promote beneficial synaptic remodeling without tumorigenic consequences. But nobody has studied this. There are no long-term safety studies. There are no carcinogenicity studies. The theoretical risk is not trivial, and it has not been addressed experimentally.

Dosing From Literature

The rat studies used intracerebroventricular (directly into the brain) administration at picomolar doses, and subcutaneous administration at approximately 2 pmol/kg. Translating this to human subcutaneous dosing involves significant uncertainty.

The community-reported doses of 5-20mg subcutaneous or intranasal have essentially no scientific basis. They are extrapolations from animal data filtered through forum consensus. The gap between the published effective dose in rats (picomolar range) and what people inject (milligrams) suggests either massive underdosing relative to bioavailability losses or massive overdosing relative to receptor activation thresholds. Nobody knows which.

PE-22-28: The BDNF Mimetic

Background and Origin

PE-22-28 is a heptapeptide (seven amino acids) derived from a structure-activity relationship study of spadin, itself a natural peptide fragment of the propeptide sortilin. The research was conducted by Jean Bhakdi-Sitte Bhakdi-Mazziotta's group (also published under Catherine bhakdi-Heurtevin's group) at the French National Centre for Scientific Research (CNRS) and collaborators.

Spadin was identified as an antagonist of the TREK-1 potassium channel, a two-pore domain potassium channel expressed widely in the brain. TREK-1 knockout mice display an antidepressant-like phenotype, which made TREK-1 blockade an attractive target for depression research.

PE-22-28 was designed as a shorter, more stable analog of spadin with improved pharmacological properties.

The Key Study

The primary paper was published in 2019 in Neuropharmacology by Djillani et al. Key findings:

• PE-22-28 blocked TREK-1 channels with low nanomolar affinity
• In mice, PE-22-28 showed antidepressant-like effects in the forced swim test and novelty suppressed feeding test after just 4 days of treatment (compared to 2-3 weeks for SSRIs)
• PE-22-28 treatment increased hippocampal BDNF levels and promoted hippocampal neurogenesis
• The compound crossed the blood-brain barrier after intraperitoneal injection
• Effects were observed at 0.5 mg/kg in mice

Why "BDNF Mimetic" Is an Oversimplification

PE-22-28 does not directly bind BDNF receptors (TrkB). Instead, TREK-1 blockade leads to increased neuronal excitability, which triggers activity-dependent BDNF release. The pathway is:

TREK-1 blockade --> increased neuronal firing --> activity-dependent BDNF transcription and release --> TrkB activation --> downstream neuroplasticity

This is an indirect mechanism. Calling PE-22-28 a "BDNF mimetic" is like calling coffee a "dopamine supplement" because caffeine indirectly increases dopamine transmission. Technically connected, but mechanistically misleading.

The Evidence Problem

Let's be blunt about the evidence base:

• One primary research paper describing PE-22-28's effects
• Mouse behavioral models only -- no rat studies, no primate studies, no human studies
• Forced swim test limitations -- this behavioral test has been increasingly criticized as a poor predictor of antidepressant efficacy in humans. Numerous compounds that "work" in forced swim test have failed in human trials.
• No pharmacokinetic data in humans -- half-life, bioavailability, tissue distribution, metabolism are all unknown
• No safety/toxicology data beyond basic tolerability in mice during short experiments

Despite this, PE-22-28 was being sold by gray-market peptide vendors within months of the paper's publication. People were injecting a compound subcutaneously based on one mouse study with an IP injection route.

TREK-1 Beyond Depression

TREK-1 channels are not only involved in mood regulation. They play roles in:

• Pain perception: TREK-1 knockout mice show increased sensitivity to painful stimuli
• Neuroprotection during ischemia: TREK-1 opening is part of the brain's protective response to oxygen deprivation
• Anesthetic sensitivity: TREK-1 is a target of volatile anesthetics
• Temperature sensing: TREK-1 channels respond to temperature changes

Chronically blocking TREK-1 could therefore have unintended effects on pain processing, stroke vulnerability, and thermoregulation. These are not theoretical concerns -- they are direct pharmacological predictions based on the channel's known biology.

The In-Vitro to In-Vivo to Clinical Chasm

Both Dihexa and PE-22-28 illustrate a fundamental problem in how the biohacking community evaluates compounds. The progression from bench to bedside is:

1. In-vitro (cell culture): Shows a compound can do something in isolated cells. Success rate to clinic: ~1 in 1,000.
2. In-vivo (animal models): Shows a compound can do something in a living organism. Success rate to clinic: ~1 in 10.
3. Phase I (human safety): Shows a compound does not kill people at tested doses. Most compounds pass this.
4. Phase II (human efficacy signal): Shows a compound might actually work. About 30% pass.
5. Phase III (confirmed efficacy): Shows a compound definitely works in a large population. About 50% of Phase II successes pass.

Dihexa has in-vivo data from one lab. PE-22-28 has in-vivo data from one study. Neither has reached Phase I. The community is treating them as if they are Phase III successes.

Risk Assessment

For advanced readers considering these compounds, here is a frank risk assessment:

Dihexa

• Theoretical benefit: Enhanced synaptogenesis, improved memory formation
• Theoretical risk: HGF/MET pathway activation has known oncogenic potential; no dose-response data in humans; no safety data of any kind in humans
• Evidence quality: One lab, animal data only, no independent replication
• Risk level: High. The oncogenic pathway concern is not speculative -- it is based on decades of cancer biology.

PE-22-28

• Theoretical benefit: Increased BDNF, antidepressant effects, possible cognitive enhancement
• Theoretical risk: TREK-1 blockade affects pain processing, neuroprotection, and thermoregulation; no human data; one mouse study
• Evidence quality: One study, one lab, mouse forced swim test only
• Risk level: High. The evidence base is almost nonexistent.

What Responsible Exploration Looks Like

If you are genuinely interested in these mechanisms rather than these specific compounds:

• For HGF/MET-mediated neuroplasticity: Follow the academic literature from Harding's lab and others working on AngIV/AT4 receptor biology. Several groups are working on safer analogs.
• For BDNF enhancement: Exercise remains the most reliable, safest, and best-studied method of increasing hippocampal BDNF in humans. A 2011 PNAS study showed that aerobic exercise increased hippocampal volume by 2% and elevated serum BDNF levels in older adults.
• For TREK-1 biology: Follow the channel pharmacology literature. If TREK-1 antagonism proves to be a viable antidepressant strategy, pharmaceutical development will eventually produce properly tested compounds.

The mechanisms are real. The science is genuinely interesting. But the leap from "interesting mechanism" to "safe to inject" requires data that does not yet exist.

Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice or an endorsement of Dihexa, PE-22-28, or any other investigational compound. Neither compound is approved for human use by any regulatory agency worldwide. The research discussed is preliminary, predominantly preclinical, and does not establish safety or efficacy in humans. Self-administration of these compounds carries unknown and potentially serious risks. Always consult a qualified healthcare professional before making decisions about your health. CompoundIQ Research assumes no liability for actions taken based on this content.